DreamCIS Past Earnings Performance
Past criteria checks 0/6
DreamCIS's earnings have been declining at an average annual rate of -2.1%, while the Life Sciences industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 28.8% per year. DreamCIS's return on equity is 6.8%, and it has net margins of 7.8%.
Key information
-2.1%
Earnings growth rate
-2.1%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 28.8% |
| Return on equity | 6.8% |
| Net Margin | 7.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How DreamCIS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 47,844 | 3,739 | 9,223 | 733 |
| 30 Sep 23 | 46,491 | 2,285 | 9,366 | 440 |
| 30 Jun 23 | 42,957 | 4,108 | 8,495 | 440 |
| 31 Mar 23 | 42,657 | 4,646 | 7,667 | 440 |
| 31 Dec 22 | 38,874 | 4,405 | 6,461 | 440 |
| 30 Sep 22 | 35,778 | 5,528 | 6,048 | 277 |
| 30 Jun 22 | 31,476 | 4,229 | 5,365 | 277 |
| 31 Mar 22 | 27,133 | 2,888 | 4,584 | 277 |
| 31 Dec 21 | 26,153 | 3,229 | 4,470 | 277 |
| 30 Sep 21 | 23,234 | 2,612 | 4,306 | 316 |
| 30 Jun 21 | 22,652 | 2,875 | 4,279 | 316 |
| 31 Mar 21 | 23,498 | 4,542 | 4,322 | 316 |
| 31 Dec 20 | 23,489 | 4,854 | 4,297 | 316 |
| 30 Sep 20 | 23,051 | 4,248 | 4,267 | 141 |
Quality Earnings: A223250 has a large one-off gain of ₩1.8B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A223250's current net profit margins (7.8%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A223250's earnings have declined by 2.1% per year over the past 5 years.
Accelerating Growth: A223250's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A223250 had negative earnings growth (-15.1%) over the past year, making it difficult to compare to the Life Sciences industry average (7.5%).
Return on Equity
High ROE: A223250's Return on Equity (6.8%) is considered low.